Drugs / Mycobacterium vaccae
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05680415 | Apr 2023 → Sep 2026 overdue | latent tuberculosis infection | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mycobacterium vaccae | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05680415 ↗ |
| Known as | Mica | “Mycobacterium vaccae for injection (Mica) :” NCT05680415 ↗ |
| Route | Intramuscular | “inject it deep into the buttocks muscle” NCT05680415 ↗ |